Wednesday, 8. May 2024 / Press Release
Athebio AG appoints Thomas Huber, PhD, as CEO
Schlieren-Zurich, Switzerland, May 08, 2024 – Athebio AG, a biotech company enabling drug developers to generate next-generation therapeutics using custom-built designed ankyrin repeat proteins (i.e., Athebody® DARPins) today announced the appointment of Thomas Huber, PhD, as Chief Executive Officer. This marks a significant milestone for Athebio AG, as Thomas brings a unique blend of scientific expertise and corporate leadership to the helm of the organization.
Thomas has held key positions at prominent pharmaceutical companies, including Novartis, Almirall, and biotech incubator Ridgeline Discovery. During his tenure at these organizations, Thomas played a pivotal role in enabling and advancing drug discovery programs, shaping corporate strategy, and leveraging his deep understanding of both scientific principles and business dynamics. “With over 15 years of experience in drug discovery, spanning from therapeutic proteins to multi-specific antibodies and adeno-associated virus-based gene therapy, I have gained valuable insights and contributed to the development of various technology platforms. Having worked hands-on with DARPins, I am passionate about the transformative potential of this technology,” said Thomas. “I am deeply honored to have been given the opportunity to lead the exceptionally talented team at Athebio AG. I eagerly anticipate continuing to push the boundaries of innovation and drive the development of novel therapeutics for patients in need.”
Thomas’ broad expertise spans across various facets of drug discovery and development, making him uniquely positioned to guide Athebio AG through its next phase of growth and expansion. His visionary leadership and strategic acumen will be instrumental in advancing the company’s mission to make Athebody® DARPins widely accessible to drug developers.
“We are thrilled to welcome Thomas as the new CEO of Athebio AG,” said Patrik Forrer, Chairman & Co-Founder at Athebio AG. “His unparalleled expertise and proven track record of success make him the ideal leader to steer the company forward and capitalize on the vast opportunities ahead. We look forward to leveraging his leadership to broadly establish Athebody® DARPins as “plug & play” building blocks for innovative drugs.”
Patrik, who has served as CEO since the company’s inception, will transition to the role of Acting Chief Scientific Officer (CSO), in addition to his position as Chairman of the Board.
For additional information, please contact us:
Phone: +41 44 508 08 28
Email: contact@athebio.com